As a Canadian in Silicon Valley, venture capitalist Ann Hanham has done it all. Her distinguished résumé includes taking the first stem cell device for approval to the Food and Drug Administration, as well as taking public a number of companies.
But after being away for over two decades, Ms. Hanham is coming home – not because the venture capital business in Canada is thriving, but because it isn’t. And she wants to change that.
“It is heartbreaking that so much talent and so much brilliant research isn’t being commercialized,” says Ms. Hanham from San Francisco, where she is currently a managing director at Burrill & Company, a venerable venture capital firm that invests money on behalf of partners such as Unilever NV, Archer- Daniels-Midland Co. and Nestlé SA.
To read the full, original article click on this link: CTV News | Venture capitalist targets biotech sector
